Skip to main content
Premium Trial:

Request an Annual Quote

Canada Clears SQI’s Celiac Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics has received clearance from the Canadian government to market its biomarker-based microarray test for celiac disease, which runs on its multiplex testing kit, the Toronto-based company said today.

Health Canada has given a medical device license to SQI’s IgX Plex Celiac microarray test kit, which measures four biomarkers, for use on the SQiDworks platform.

Celiac disease is a digestive tract condition caused by the consumption of gluten that causes an immune reaction in the small intestine leading to damage to its surface and affecting its ability to absorb nutrients.

"As more assays become commercially available, the potential return on investment for labs that are considering purchasing the [SQI] technology increases, which may ultimately accelerate SQI's revenue ramp,” company President and CEO Claude Ricks said in a statement.

The company also said that it has submitted a 510(k) application with the US Food and Drug Administration for its Plex Celiac Assay and the SQiDworks diagnostics platform, and that the regulatory approval process is currently “on track.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more